Lundbeck Canada

Lundbeck Canada is the Canadian presence of Lundbeck, a global pharmaceutical company specialized in brain diseases. Lundbeck is engaged in the research, development, manufacturing, and commercialization of pharmaceuticals across the world, and has been at the forefront of neuroscience research for more than 70 years. The Canadian site highlights regulatory and access milestones such as Health Canada approval of ABILIFY MAINTENA and public drug plan coverage of Vyepti for migraine prevention.

Lundbeck was founded on 14 August 1915 by Hans Lundbeck in Copenhagen, Denmark, initially as a trading company dealing in machinery, biscuits, confectionery, sweeteners, cinema equipment, cameras, photographic paper, aluminum foil, and vacuum cleaner rentals. From the mid-1920s, pharmaceuticals of all sorts were added to its range. Eduard Goldschmidt was hired in 1924, bringing experience from the chemical and pharmaceutical industries and new agency contracts for pharmaceuticals such as suppositories and painkillers; cologne and creams were also added, and the company acquired its first tablet compression machine. The Canadian site presents Lundbeck as a global pharmaceutical company specialized in brain diseases, engaged in research, development, manufacturing, and commercialization of pharmaceuticals across the world, with more than 70 years of neuroscience expertise.

One of the only biopharmaceutical companies in the world focusing exclusively on brain diseases, set apart by specialization.

• ABILIFY MAINTENA (aripiprazole for prolonged release injectable suspension)

• Vyepti (eptinezumab)

1. 1Homelundbeck.com
2. 2Our historylundbeck.com
3. 3About uslundbeck.com